- Home
- Equipment
- usa arizona
- bioptic
Refine by
Bioptic Equipment Supplied In Usa Arizona
5 equipment items found
Manufactured by:International Polymer Engineering, Inc. (IPE) based inTempe, ARIZONA (USA)
IPE’s flexible and bendable FluoroFlex biopsy channel components combine the best properties of both PTFE and ePTFE in a composite construction. FluoroFlex biopsy channel components helps guard against kinking and is adapted to be insertable, in-line, with the rigid section of the endoscopic working channel. FluoroFlex significantly reduces friction within the endoscope for easy ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Increased Clarity for Difficult-to-Diagnose Melanocytic Lesions. MyPath Melanoma and DecisionDx DiffDx Melanoma gene expression profile (GEP) tests are designed to provide objective information to aid in the diagnosis and inform management decisions for patients with ambiguous melanocytic ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Our DecisionDx-UMSeq is a 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma. Researchers believe that identifying mutations in tumor genes may someday help guide treatment decisions. Because the amount of tumor biopsy tissue is limited, it is important to gain as much information as possible about a uveal melanoma tumor from a single ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Predicting Individual Risk of Metastasis: DecisionDx-SCC is now commercially available. DecisionDx-SCC is clinically validated as a significant predictor of metastasis and the strongest predictor of risk compared to traditional clinical and pathological factors. DecisionDx-SCC complements traditional prognostic risk assessment factors, enabling more informed choices about treatment and follow-up ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Predicting Individual Risk of Recurrence or Metastasis: DecisionDx-Melanoma was designed to address the need for a more accurate predictor of metastatic risk in patients diagnosed with cutaneous (skin) melanoma. ...